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Methods: We studied 65 pts (50 men, 15 women; moan age 52 ym) with 
EBCT who h0d Route myocordlol infarction (AMI) os their first cllnloal msnl. 
fostatlon of CAD. EBCT woe performed a mean of 25 day8 after Inferctlon, 
Results: CAC was pro80nt In 59 of 0`5 pie (91%), wlth n mann score of 
471) :L 551 (range 0-2401), el note, 4 of 0 pie without CAC hod one vessel 
CAD And Intracoronsry stont8 placed prior to EBCT, possibly masking CAC 
detection, The CAC 8~om, Adjusted for patient Age, w~s severn In 35 (54%); 
moderate In 11 (17%); and mild In 13 (20%~ pts, We hsve previously shown 
thst <10% of pie with CAC scores <400 have abnormal sims8 myocardial 
porfuslon scans, Importantly, 51% of our pie= had CAC scorer <400 And 80 
might not have boon dst~otod n9 having CAD by other 8Gm8nlng tost~, 6gob 
¢ttl a~omlso poduslon Imaging, 
Conclusion: Most pts who present with AMI as t1181r first manlf88tlltton ol
CAD have CAC, The I,~k el CAC, therefore, should predict A population ~t 
very low rl~k lot CAD and sobsequont oardlso events, 
3:15 
~ 3 , ~  Yurm Follow,up of Asymptomatl© 11311 Adults 
Undergoing Electron Basm CT (EBCT) of the 
Comn#~ Artsrlsl 
Y, A~fl, LA, ~podnm, K, Goods,n, A, Lledo, ~, 9herman, A,D, QuAsi, St, 
Fr'dncl~ H~pft~ll, Rotten, N, Y, USA 
In order to determine the Intermediate term pmgnostlo aoC:ur~Cy (~t EaCT 
ds A l!cmonlng test for coronary artow disease, wo qllerlod 1173 initially 
Asymplomnlto ~dult~ 3,0, yearn (range 38 to 47 months) alter sonnntngl, t136 
(97%) replied; olforls to centaur the missing subjects mml~ln gndm way, 
Al the time of sosnnlng, me~n age was ~3 ± 11 yasm sad median (25%, 
75%) Corons~ ¢alclt~m scorn (CC~) wpls 4 (0, 9B), At follow.up, 40 patlent~ 
h~d 8usteltne~l camlovnscular doeth (2), nonfatal MI (14), CABG (14), or 
PTCA (10) Iovent rate 3,5%1, Medteln CCS was 655 (lUll, 872) among thos~ 
with events emd 4 (0, £tl) among those without events (p -: 0`.0001) 
Sensitivity, specificity, positive snd negative pmdiotivo values, overall an. 
curacy (OA) and odds ratios Am tabtllated below 1o1 events, CCS thresholds, 
and group8 of Interest, 
EvonlatGmol~ CC~ 9one Spoc PPV NPV OA OR P 
NPNI : 100 ~80~ 0,85 016 000~ 085 23 - 00001 
MI, do~th/NI 160 081 08~ 0 07 0991' 0.84 22 .00001 
Atl/AIt :600 0,55 085 0~a 0983 084 24 • 00001 
All/Men ;100 08~ 084 01a 0091 085 25 ,00001 
AlINVom~n .160 011 0.SB 0,11 0893 087 18 -0.001 
In asymplomalic, ~ppamntly hoallhy adults, EBCT is highly predictive oi 
cardiovascular events over the ensuing 3 to 4 years. 
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~ Incidence and Predlctom of Anglographlc 
Restanosis snd Reoccluslon Alter Primary Infarct 
Slanting - Core lab Analysis From the PAMI Stent 
Pilot Study 
J. Griffin, B, Brodie, M-C. Morice, C. Costantini, J. Popma, P,A. Overlie, 
F, St, Gear, J.G, Kenersoo, A. Merrill, S. Thoodostou, J.A, McDonnell, 
W.W, O'NeilL C,L, Gnnos, G,W. Stone. The Cardiovascular Instatute, El 
Camino Hospital Mountain View, CA, USA 
Acute infarct stenting has the potential to reduce 1he high rate of restenosis 
after prima~ PTCA, reported in 5 poor series to be 37%.--49% (including 
9%-13% infarct artery mOcclusion). In the prospective PAMI Steal Pilot Trial, 
stenting was performed in 240 consecutive pts with AMI and eligible vessels 
at 9 centers (98% success rate). A mean of 1 4 i 0.7 slants were implanted 
per pt (range 1-7) at 17.3 ~ 2.4 aim.; 97% were Palmaz-Schatz, Of 229 
stented pts discharged without in-hAsp. CABG, angiographic follow.up was 
performeO m 176 pts (77%) at mean time oi 7,7 ± 3.4 months Index and 
follow-up films were analyzed at an independent core lab (Wash. HAsp. 
Cntr.). TIMI-3 flow (core lab) was restored in 95,5% of pts after stenting. 
Angiogmphic measures are shown in table. 
The late loss index was 0.33 J: 0.36. Restenosis (DS >50%) occurred 
in 25,2% of pts, including 5.6% infamt artery reocclusion, 51 procedural, 
technical and angiographic variables were examined lor their relationship 
to reslonosis. The only correlate of restenosis was the number of stents 
Pro Imm, pest Follow.up 
Reference ~og (ms) 3,08 t. 0,0~ 3,19 t O51 3,09 t 0,55 
MLD (ms) 0,27 :*- 0,56 2,85 t. 0,51 202  ¢ 091 
Oinmntor Mono~is (%) 89,1 t 180 10,4 t 120 340  ~ 270 
implsntod (20,6% with 1 stoat, 32,5% with 2 8tent8 and 50,0% with '~3 
stonts, p = 0,07), The only pmdlotor of reo¢¢luslon waA the final I~lloon 
dlamstor (12,1% with ~3,0 mm bsl, ve, I~,1% with ~,~1,25 mm I~1,, p =, 0,01), 
Conclusions: The date from this 18rg0, pro~p~tlve multt¢entAr 8lAdY 8gO, 
goats thst prlmAty 8tenting In AMI mdg~ msten~i8 And infarct Artery 
mocd~mlon Compared to prlmsq/PTCA Alone, 
2:30 
~ Pr!mary Anglopluty for Acute Myocardial Infamtlon 
at Hospitals With No Surgery On-81te: The 
Prospective Mull!center PAMI,No SOIl Reg!Mry 
tP, Whmlon, J,D, Johnston, M,A, Ttlrco, J, ~!ithet, D,C~ Lew, W, Oi!!no~i, 
5,K, Slnghi, M Graham, L. Grihes, W,D, Weaver, C,L Qltnes, Wdl~n 
80~ltt11~rlt Ho.~fat, Royal O~k, MI and Exeter Hosl:~tat, ~ le t ,  NH, U~°~ 
Prtm~n/angioplasly (PA) prowdes supmtor Outcomes ~red  to throm. 
holysi8 (TL) tar patients (pts) with acute myocardia! inlamtion (AMI), b~d 
ilS I~tential for widespread use.especially in community hospitals with no 
pardine surgoly on.site (No SOS}.may be limited. This issue is even more 
relevant in thmmbolylio.eligible (TL.E) pls, tar whom an almmarive mpadu- 
sion me~lalkty el(ists. We sought to investigate the safety end elflicacy O1 PA 
in hiQtl,llsk TL-IE pta when pedolmed at hospitals wlth No SOS, 
I~thods: We orgafltted Anational registly a114 community besl~tals with 
No SOS whom expelienced operates mulinety porfom~ PA around-the-clock 
as tirol-line treatment far pts with AML To allow comparison to the ongmn9 
AIR PAMt Trial, pts were prospectively consented if they met AIR PAMi 
criteria: TL-E end at high risk (age 270, anlenor MI, LBBB, HR >100, BP 
.: 100, Kiilip Class, 2-.3) without shock, 
Re,suits: 266 TL-E pts with high-risk AMI had emergent calh with PTC/~ 
slant standby, tar which monitored data am available in 164. Enrollment is 
ongoing, 41% worn ~70 ym old; 46% had antenor MI. Due to No SOS. 
infarct arteries were no1 dilated if they had initial TIMI 3 flow (n = 18) or 
worn technically tnapprepnate (n = 6). Thus, PTCA was performed in 140 
(85)%, with stenhog in 46% el these. The mean time trem ER to oath was 
100 sin. Precoduml success rate" (TIMI 2 flow and <50% residaal) was 
98.6%, Emergent ransfer tar CABG was required in 2 pts (1.4%): one for 
a PA complication, and one for high-risk anatomy with no PTCA performed. 
Mean length-el-stay was 5,4 days. The combined pnman] endpoint oocuned 
in 4 pts (2.9%): in-hospital death in 2 (1.4%); CK-MB rmelevation ~n none: 
and CVA in 2 (1.4%). No pt died because o1 a complicalion ut oath o¢ 
PTCA, 
Conclusion: Tbls hmt report tram a prospective multicentor egistry el 
primary angioplasty at hospitals without celiac surgew indicates that PTCA 
in this setting can be provided solely and effectively in high-risk patients, wtlh 
outcomes that compare yen/favorably to those repotted Ires high-volume 
surgical centare. The lack st cardiac surges/need not limit the application st 
this valuable sodality in the treatment of AMI, 
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~ Angloplasty Versus Thrombolytlcs for Patients 
Presenting With Congestive Heart Failure; GUSTO 
lib Substudy Findings 
J.S. Hochman, WA. Jaber, E.R. Bates, D.A. Criger, J. Boland. 
C. VassanoIli, EJ. Topoi, S.G. Ellis. St. Luke's. Roosevelt Hospital Center. 
Columbia Universi~ NY, NY, USA 
Background: Although tnrombolytic therapy has reduced mortality for patients 
presenting with AMt and CHF, adverse events rates remain high. Pnor repeals 
suggest a greater benefit for direct PTCA over thrombotysis for patients with 
CHF. 
Killip II/tll Kiilip I 
PTCA IPA RR, CI PTCA IPA RR. Cl 
n = 46 n = 49 (95%) n = 509 n = 525 (95%) 
30 day death, 10.2% 21,700 0.41 8.9% 12.8% 0.68 
rO-MI, CVA (0.13-1.31) (0.44-0.89) 
p=016 p=0045 
6rnonlhdeath 12.2% 24.4% 043 6.6% 7.0% 0.94 
(0.15-I.29) (0.58-1.53) 
p= 0.18 p = 0.90 
IABP use 20.4% 109% p = 0.26 12.8°'o 6.3% p = 0.0004 
JACC Fchm;t~, Iq98 ABSTRACTS ,- ()rat 21 ! A 
M~thods: We evaluated the outcome for patients who pro~entod in Killip 
II and III in the GUSTO lib substudy, the largest randomized trial of direct 
PTCA vemu': thmmbolysis 
Results: This CHF group w~s older (66.6 ym vs 69,,0 yrs, p ~ 0001 ) end 
with higher mine of pnor angina (51.6% vs 386%, p = 0,016), prior CHF 
(5,3% vS 1,3%, 1~ < 001), and GOPD (8,G% vs 12%, p - 0,00t) than the 
Killip I gn~p, 
~ ;  A ~  this i$ the I ~  humber o! ipatteht~, with CHF ran~ 
domized to PTCA v~ thrombOSiS, the ~n'~le si;~ is small, The~e findings, 
whi~ 1101 stattM¢ally s~nif¢ant, raise_ the IgOtL~ntia! of a~ gro~ter benefit for 
PTCA at 30 d,i~ys and O month~ in patients presenting in Ki!lip classes II and 
lit compticat~_ an AML A I~ ,  Irml would be needed to resolve this iSSUe, 
~nd to inve~ti~to a~ potential role for adjgn~rve therapy. 
3:00 
~ IBone~ of !~immy Ang!opla!~/in IP~tkmts 
.~m..ling ~ W~h ST Segment Zk.mtio~ and 
ACuAe MyO¢#!'dLM far¢tk~ 
WJ, French, M,J, S~,  Fr~ pt~e Na~l  ~ et ~n~zt  Inaction 
(NRMt-2~ Ireves~tc~S: H a ~  Medial Center, Tonance~ CaMom~ 
Primary PTCA (P  PTCA) is used m lmaWnem at ~atmnts with acute myocar, 
~al infarcteo~, but Its effective~=se in late presenters has not been defined. 
3 ,~ Pts were evahJated with ST ele~atto~ who presented more than 12 
his afte~ s~ onset but ethan=so were el~3ble fo~ thrembo~ therapy (Try), 
and were e~ro~;J m NRMI-2 between 1994 and 1996. PtS in ~hock or who 
~ TTx were exclu~,~. TI~ mvasn~e group ~ 568 pts ~he unc~r- 
~nt  Ca~ within 6 I'ers o! ~ with 80%, hav~cJ 1~ PTCA. The med/(~! 
merapy (MTX) group included IN%. m 2.g82 I~S. The mvastve group were 
yoong~r (60.9 vs 6S.7 yre), more t'~=ty ma~e (66.2 vs 59.6%) w~ a 
of PTCA (8.1 vs 4.3%), but hess ~kety to have had CHF (3.7 vs 8.1%) or 
CABG (4.6 vs 8(P~, all p < 0.001). ~ pts m the invas~ve group were 
more likely tO be in K~p class I (82.8 v'S 7"7.7%, p < 0.001), other pmsentir~ 
Characto~ were s~mdar to pta m ~e ~,TTX group. The ewasp~ gro~p were 
more likely to receeve belPano (93.3 vs 81 5%). aspmn (896 ve 62.2%), and 
IV beta blockers (19.1 trS 142%, ~ p < 0-001) wdhm 24 hm of ad~issmn. 
In-has.tel me~tatrty m the mvasnm group was 2.8%, compared with 7.8% m 
the MIX  geoup (p < 0001). After multivariate ad[ustn~nt, the i ~  group 
were less likely to die than those in the MI"X grot~ (odds rst~o 0.47. 95% 
cord derto~ interval 027 to 0.82). 
C,~nctus~q: Pts with acute myocar~al infarction who presented more than 
1~ hours after s~om onset appear to benefit from primary ang~oplasty 
3:15 
~ Improving Outcomes in Undergoing Patients 
Primary Angiopiasty for Acute Myocardial Infarction: 
..~:=.,d Data From t~= National Registry of Myocardial 
Infarction 2
A.J. l~etenbmnn, N. Every. SR. Pirzeda, W.J. French. W.D. Weaver, 
W.J. Rogers. Washington ~ts~p/  School of Medicine, St. Louts, MO, USA 
Although there is increasing use of angmplasty (PTCA) for acute rnyocar0iai 
infarction (MI). little data about trends are available, Nalwnal Registry of 
Myocardial InfarcOon 2. an ongoing study, collects data that can be used to 
assess trends for this reperfusion modality. Data from rwe 6 month periods 
from July 1994 through December 1996 were analyzed. 
Of over 100,000 patients with ST elevabon recennng reperfirsi0n, use of 
primary PTCA increased from 9.6% to 12.3%. There were no differences in 
mean age or proportion over 75 yrs, male, antedor MI. or w~th Shock. All 
trends in the table are statistically significant. Mean door to balloon time and 
in-hospital mortality have decreased, although more patients are TTMI "not 
Im~ dsk." The use of stents and/or antiplatelet herapy ether than aSpinn has 
increased, while repeat PTCA has decreased. 
Study Period 1 2 3 4 5 
Pnmary PTCA (%) 9 6 9 9 11 4 120 12 3 
Mean Door to Balloon ~,min) 179 164 160 159 157 
TIMI e0t tow nsk (%) 44 1 448 47 5 471 499 
Mortality (%) 7.4 75 6 8 6.3 
Non ASA Antnplatelet (%) 3.6 42 72 16.2 25 7 
Stent (%) 6.6 8.6 12.4 209 248 
Second PTCA (%) 17.9 14.1 12.2 12 7 10.7 
These unaJjusted trend data indicate increased use of priman] PTCA. 
earlier therapy, and improving clinical outcomes. 
[~  Randomized Trials of Antlhypertenslve 
Agents 
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~ Blood Pmuum Low~lng in Pltlentt With 
~febfovnru!lr Oifl~l#: Flnullo of t l~ 
R=ndomlmd I=ott-Mmlw Ant~s l~ 
~ t  Study (~Ts) 
L, IJu, L Gong, Ji Ggang W~ng, For ~ PATS Invem~fom; Card~ova~:utat 
tnstrtute and F~i  ~a l ,  Bet~,  Chm~ 
Background: The raedOrm~e~ Po~t-atroke Anlihype~msNe Troa~tmef~ Sludy 
(PATS) aimed at detanlnmmg whether antlhypeflenslve (~g ~ COuld 
re~ the .sk of stroke incidence and ethel caKliovascutar comptw.,atiorm in 
patrenfs wllh a history 0f stroke or lm~ent  iscl~n~ sttack (TIA), 
Mett~od~: A tolal el ~5 pa~tmnl~ were falld~mzed (2B41 Io ~ treat. 
merit, took 2.5 mg indapam;cl~ per day; 2824 t0 placebo look (me taDlet at 
placebo), Age (±SD) averaged 60 +_ 6 yearn, 2f~-~o were women, and 64% 
were is¢fiem=c, Mea~ BP was 154/93 mmHg, In 913 (16%) subiects BP was 
below 1 ~  mmHg 
R~."  Average follOW-Up ap~roximarod to 2 ~P.am. The three-year aver- 
age BP was 149/89 mmHg for the placebo group and 14,4~7 mm Hg fo~ the 
indapan,~cle group, mspectwety. The three-year fatal and nonfatal stroke incl, 
¢lence rate was 12.1% for placebo and82% for ~ .  The relatwe ns*~ 
~ hazards regressmn anatyam was 0.69 (95% Cl: 0.57~.85, 
P < 0.001). In g13 normot~ ~ lhe three-year cumulative stroke 
inc1OenCe rate was B.7% for i'n~apamide growls and 49% for placebo group 
Relative risk for all cause mortaJity was 0.92 (95% CI: 0.74-I .14, P = 0.45) 
malt sul~ecta. 
Conc/us~o~ In post-stroke pahents with or w~theut h~gh I~lood pressure, 
BP reductmn of 5/2 mmHg with 2.5 mg indaparn~e per day reduced the fatal 
and nonfatal stroke incidence by 31%. 
2:15 
~ Effect  o f  Ramipf l l  A f te r  Myocardia l  Acute In farct ion  
in Pat ients W'dlt Ar t l~ml  Hyper tens ion  
CS.  Sparglas, A.S. Hdii, S+G. Ball. Inshlufe for Cardiovascular Research, 
~rs rZy  ot Leeds, UK 
Background" After myocardial |nfarctlon (MI), patients with a history of aria- 
nat hypertensxon (AH) have a worse prognosis than that of normotons~ves. 
Ang~otensm coxwemng enzyme (ACE) mhibdlon post MI substantially im- 
proves survival in high nsk populahons. This study evaluates the influence o! 
a ~story of ,~H on the efficacy of ACE inhibition post MI. 
Meff/oGs: We ~ e t y  analyzed dela from the AIRE study (random- 
ized. p l~t ro t led  trial ot ramipfit m 2006 post MI patients with cltnma! 
e~clence o! hear faiture-HF). At baseline, 28% o! the pahents had a histoW 
of" AH. We exammecl the effect of rarn~pnl on clm~al outcomes according to 
whether or not a history of AH was p,esent. To adjust for baseline chnrcal 
differerces, 16 vanables were ~imultaneously entered in a mufflvanete Cox 
regression model. 
Results: Treatment with ramtpnt resulted in a significant reduction in the 
risk of all-cause modality in the llypertensive patients (32%, CI 1% to 54%, p 
= 004) but not m the normotensNe group (14%, CI - 11 to 34%, NS). There 
was also an associated trend toward lower HF- morbidity in the hypertensives 
(31%, Ct -4  to 46%. p = 0.07) but not in the normotens~ves (5%, CI -26 to 
28%, NS). 
Conclusion: Our data indicate that ACE inhibition, in patvents with clinmal 
evidence of HF post MI, is of pa~cular benefit to those w~th a history of AH 
2:30 
~ A  Study on Optimal Treatment f l~rmt~SS H 
St,a;~=gles for Hypertension and CAD: Pilot PhaSe 
Data From the INternational VErapamll-trandoiapril 
STudy (INVEST) 
C.J. Pepine. M. Conlon. E. Hancfoerg-Tbermond, R G. Marks. 
R. Cooper-DeHoff. H Robert Kelb. University of Florida, Gainestfilte. 
Florida, USA 
The INVEST is a trial to assess whether a calcium a~agonist treatment 
strategy is equivalent o a noncalciurn antagonist strategy (JNC V) to prevent 
adverse outcomes in 27.000 patients with hypertension and CAD. Patients 
are being enrolled at 1,500 primary care sites using a novel electromc sys- 
tern for direct on-screen data entry, randomization and drug distnbut~on from 
